HOUSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ('Moleculin” or the 'Company”), today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on October 20, 2026, and the Company’s common stock will open for trading on The Nasdaq Capital Market

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. ('Alector,” Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the pricing of an underwritten offering of common stock. Alector is selling 36,600,000 shares of common stock. The shares of common stock are being sold at an offering price of $2.05 per share, which represents a premium of approximately 7.3% over the closing

Fusion Fuel reported its first-half 2026 results and guided to full-year revenue of €16 million to €18 million, an increase of 11%–25% year over year. Its non-IFRS adjusted operating loss narrowed by about 25% to roughly €1.8 million. In July the company completed its acquisition of Royal Uranium, adding interests in uranium and natural gas project areas. Its BrightHy Solutions unit started a 2 MW industrial green hydrogen project in Spain and contributed about €369,000 in engineering revenue during the half.

TORONTO and PERTH, Western Australia, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Cygnus Metals Limited (ASX:CY5, TSXV:CYG, OTCQB:CYGGF) ('Cygnus” or the 'Company”) provides the following update in relation to the proposed transaction under which Central Asia Metals PLC (AIM:CAML) ('CAML”) will acquire 100% of the shares in Cygnus pursuant to a scheme of arrangement under Part 5.1 of the Corporations Act 2001 (Cth) ('Scheme”).

Ollie's Bargain Outlet Holdings' board of directors unanimously approved a new $500 million share repurchase authorization. Combined with its existing authorization, the company now has approximately $561 million in aggregate repurchase capacity. Since launching its buyback program in 2019, the retailer has returned roughly $679 million to shareholders. It has also continued to invest in new stores, supply chain capacity and strategic growth initiatives.

Gevo said it has sold and delivered 10,000 carbon dioxide removal credits through ClimeFi to an end corporate buyer. The company said its existing sequestration infrastructure, operating footprint and access to both compliance and voluntary carbon markets could support a carbon business generating more than $30 million in annual revenue. Industry data show that only about 3% of roughly 50 million contracted tons in the carbon dioxide removal market has been delivered.

Beeline Holdings expects third-quarter 2026 revenue to reach its highest level since 2021 and to post record margins. The company also forecasts a narrower net loss and its lowest adjusted EBITDA loss in five years. Beeline expects its end-of-quarter cash balance to be at least 50% higher than at the end of Q2 2026.

Blaize said it expects preliminary third-quarter 2026 revenue of about $0.5 million for the period ended September 30, 2026. The company lowered its full-year 2026 revenue guidance to a range of $32.0 million to $36.0 million. It said the updated outlook is based on binding, noncancellable purchase orders from NeoTensr and a new purchase order from an existing customer that is in the process of being signed. Blaize added that shipments to NeoTensr during the quarter relate to the contract it announced in April 2026 for up to $50.0 million.

Biotechnology company Spyre Therapeutics said it has priced its underwritten public offering of 4,117,648 shares of common stock at $85.00 per share. The company expects gross proceeds of about $350.0 million, before underwriting discounts and offering expenses.